search
Back to results

Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia (INPACT-DEEP)

Primary Purpose

Critical Lower Limb Ischemia

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
IN.PACT Amphirion
Standard PTA
Sponsored by
Medtronic Endovascular
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Lower Limb Ischemia focused on measuring BTK, CLI, PTA

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

General Inclusion Criteria

  • Age ≥18 years and ≤85 years
  • Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an Ethical Committee approved consent form
  • Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
  • Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 4, 5 or 6
  • Life expectancy >1 year in the Investigator's opinion

General Angiographic Inclusion Criteria

  • Reference vessel(s) diameter between 2 and 4 mm
  • Single or multiple lesions with ≥70% diameter stenosis (DS) of different lengths in one or more main afferent crural vessels including the tibioperoneal trunk
  • At least one non occluded crural vessel with angiographically documented run-off to the foot either direct or through collaterals

Angiographic Inclusion Criteria for Late Lumen Loss (LLL) assessment

  • Angio-target lesion (TL) is one identifiable single solitary or series of multiple adjacent lesions with a diameter stenosis (DS) ≥70% and a cumulative length ≤100 mm that can be covered by a single IN.PACT Amphirion™ (10 mm balloon landing zone in both edges is mandatory)
  • Angio-target lesion (TL) is the only lesion in that vessel (only one Angio-TL per patient is allowed)

Exclusion Criteria:

General Exclusion Criteria

  • Patient unwilling or unlikely to comply with Follow-Up schedule
  • Planned major index limb amputation

General Angiographic Exclusion Criteria

  • Lesion and / or occlusions located or extending in the popliteal artery or below the ankle joint space
  • Inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA), popliteal arteries with length ≥15 cm
  • Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA) and popliteal arteries left untreated
  • Previously implanted stent in the target lesions(s)
  • Aneurysm in the target vessel
  • Acute thrombus in the target limb

General Procedural Exclusion Criteria

  • Failure to obtain a <30% residual stenosis in pre-existing, hemodynamically significant (≥50% diameter stenosis (DS) and <15 cm length) inflow lesions in the ipsilateral iliac, SFA and popliteal artery. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions.
  • Failure to cross the TL with a 0.014" guide wire
  • Use of alternative therapy, e.g. atherectomy, cutting balloon, laser, radiation therapy, DES as part of the index procedure

ANGIOGRAPHIC cohort General Exclusion Criteria:

- Glomerular Filtration Rate (GFR) <30 ml/min except for patients with renal end stage disease on chronic haemodialysis

Sites / Locations

  • Medical University Graz
  • Imelda Hospital
  • AZ Sint-Blasius
  • ZOL St. Jan
  • Ghent University Hospital
  • Herz-Zentrum Bad Krozingen
  • Medical Care Center
  • University Hospital Heidelberg
  • Park-Krankenhaus Leipzig
  • Villa Maria Eleonora Hospital
  • St. Antonius Hospital
  • University of Bern
  • Luzerner Kantonsspital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Drug Eluting Balloon

Standard PTA

Arm Description

Intervention: IN.PACT Amphirion™

Intervention: Standard PTA

Outcomes

Primary Outcome Measures

Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA)
The difference between minimum lumen diameter (MLD) immediately after Percutaneous Transluminal Angioplasty (PTA) and MLD at 12 months follow-up
Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients
Percentage of participants in the amputation free survival population with Clinically driven Target Lesion Revascularization (CD-TLR) at 12 months, CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s).
Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR)
Percentage of participants experiencing all cause death, major amputation and clinically driven Target Lesion Revascularization (CD-TLR) at 6 months. CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s)

Secondary Outcome Measures

Amputation Free Survival
Percentage of participants with a 1 year amputation free survival.
Rate of Wound Healing
Percentage of participants with completed wound healing, wound healing as defined as core lab adjudication of > 50% area/volume reduction of baseline ulcer(s) in the treated leg at 1 year.
Amputation Free Survival and Wound Healing
Percentage of participants with a 1 year amputation free survival and wound healing. Wound healing is defined as core lab adjudication of > 50% area/volume reduction of baseline ulcer(s) in the treated leg at a specified time point.
Amputation Free Survival and Resolved Critical Limb Ischemia (CLI)
Percentage of participants with an amputation free survival and resolved Critical Limb Ischemia (CLI) at 1 year.
Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR)
Percentage of participants that experienced death, amputation and clinically driven Target Lesion Revascularization (TLR) at 1 year.
Primary Sustained Clinical Improvement
Percentage of participants that experienced primary sustained clinical improvement at 1 year, specified as an improvement shift in the Rutherford classification of one class in amputation free, clinically driven target lesion revascularization (TLR) free surviving subjects.
Secondary Sustained Clinical Improvement
Percentage of participants that experienced a secondary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class including the need for clinically driven TLR in amputation free surviving subjects at 1 year.
Quality of Life Assessment by EQ5D
Quality of life assessment by EQ5D at 1 year compared to baseline. EQ-5D is a standardised measure of health status and economic appraisal. The EQ-5D-3L essentially consists of 2 parts:the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. EQ-5D health states can be converted into a single summary index where 0.0='worst possible outcome' and 1.0='best possible outcome'.
Walking Capacity Assessment
Walking Impairment assessment by WIQ at 1 year compared to baseline. The Walking Impairment Questionnaire (WIQ) is a questionnaire for evaluating walking impairment in patients with peripheral arterial disease (PAD). This can be used to identify patients with significant impairment and to monitor effectiveness of therapeutic interventions. The questionnaire was self-administered by the patients and contains three domains measuring three important factors of walking impairment in patients with intermittent claudication: (1) difficulty walking a distance during the past month, (2) difficulty walking at a certain speed during the past month, (3) symptoms associated with walking impairment. For each separate domain, a subscore was calculated. The total WIQ score was defined as the mean of the three subscores. A WIQ score of 42.5 or less identified low performers; while a score of 75.5 or more identified high performers. The WIQ score range is 0 (minimum) - 100 (maximum).
MAE (Major Adverse Events)
Percentage of participants with a MAE (Major Adverse Events) at 1 year. Major Adverse Events, defined as Death of any Cause, Major Amputation of target limb, Minor Amputation of target limb
Device Success
Percentage of device success defined as exact deployment of the device according to the instructions for use as documented with suitable imaging modalities
Technical Success
Percentage of technical success defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with less or equal to 50% residual diameter reduction of the treated lesion on completion angiography
Procedural Success
Percentage of patients with a procedural success defined as combination of technical success, device success and absence of procedural complications
Days of Hospitalization
Days of hospitalization at 1 year
Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA)
Percentage of participants with an improvement in percent diameter stenosis (%DS) of the target leasion (TL) assessed by Quantitative Vascular Angiography (QVA)

Full Information

First Posted
July 16, 2009
Last Updated
January 31, 2018
Sponsor
Medtronic Endovascular
search

1. Study Identification

Unique Protocol Identification Number
NCT00941733
Brief Title
Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Acronym
INPACT-DEEP
Official Title
Randomized Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA (Percutaneous Transluminal Angioplasty) for the Treatment of Below the Knee Critical Limb Ischemia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
November 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Endovascular

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, multi-center, randomized (2:1) trial of symptomatic patients with critical limb ischemia (CLI) secondary to atherosclerotic lesions (stenotic or occluded) of the infrapopliteal vessels. Patients will undergo a percutaneous transluminal endovascular procedure with either the IN.PACT Amphirion™ drug eluting balloon or with a standard (Percutaneous Transluminal Angioplasty) PTA balloon. Patients will be followed with pre-study, post-study, and follow-up evaluations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Lower Limb Ischemia
Keywords
BTK, CLI, PTA

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
358 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Drug Eluting Balloon
Arm Type
Experimental
Arm Description
Intervention: IN.PACT Amphirion™
Arm Title
Standard PTA
Arm Type
Active Comparator
Arm Description
Intervention: Standard PTA
Intervention Type
Device
Intervention Name(s)
IN.PACT Amphirion
Intervention Description
Balloon Angioplasty
Intervention Type
Device
Intervention Name(s)
Standard PTA
Intervention Description
Balloon Angioplasty
Primary Outcome Measure Information:
Title
Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA)
Description
The difference between minimum lumen diameter (MLD) immediately after Percutaneous Transluminal Angioplasty (PTA) and MLD at 12 months follow-up
Time Frame
12 months or at Target Lesion Revascularization (TLR) time
Title
Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients
Description
Percentage of participants in the amputation free survival population with Clinically driven Target Lesion Revascularization (CD-TLR) at 12 months, CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s).
Time Frame
12 months
Title
Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR)
Description
Percentage of participants experiencing all cause death, major amputation and clinically driven Target Lesion Revascularization (CD-TLR) at 6 months. CD-TLR defined as any TLR of the target lesion associated with Deterioration of Rutherford Class and / or increase in size of pre-existing wounds and / or occurrence of a new wound(s)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Amputation Free Survival
Description
Percentage of participants with a 1 year amputation free survival.
Time Frame
12 months
Title
Rate of Wound Healing
Description
Percentage of participants with completed wound healing, wound healing as defined as core lab adjudication of > 50% area/volume reduction of baseline ulcer(s) in the treated leg at 1 year.
Time Frame
12 months
Title
Amputation Free Survival and Wound Healing
Description
Percentage of participants with a 1 year amputation free survival and wound healing. Wound healing is defined as core lab adjudication of > 50% area/volume reduction of baseline ulcer(s) in the treated leg at a specified time point.
Time Frame
12 months
Title
Amputation Free Survival and Resolved Critical Limb Ischemia (CLI)
Description
Percentage of participants with an amputation free survival and resolved Critical Limb Ischemia (CLI) at 1 year.
Time Frame
12 months
Title
Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR)
Description
Percentage of participants that experienced death, amputation and clinically driven Target Lesion Revascularization (TLR) at 1 year.
Time Frame
12 months
Title
Primary Sustained Clinical Improvement
Description
Percentage of participants that experienced primary sustained clinical improvement at 1 year, specified as an improvement shift in the Rutherford classification of one class in amputation free, clinically driven target lesion revascularization (TLR) free surviving subjects.
Time Frame
12 months
Title
Secondary Sustained Clinical Improvement
Description
Percentage of participants that experienced a secondary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class including the need for clinically driven TLR in amputation free surviving subjects at 1 year.
Time Frame
12 months
Title
Quality of Life Assessment by EQ5D
Description
Quality of life assessment by EQ5D at 1 year compared to baseline. EQ-5D is a standardised measure of health status and economic appraisal. The EQ-5D-3L essentially consists of 2 parts:the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: (1) no problems, (2) some problems, (3) extreme problems. The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. EQ-5D health states can be converted into a single summary index where 0.0='worst possible outcome' and 1.0='best possible outcome'.
Time Frame
12 months
Title
Walking Capacity Assessment
Description
Walking Impairment assessment by WIQ at 1 year compared to baseline. The Walking Impairment Questionnaire (WIQ) is a questionnaire for evaluating walking impairment in patients with peripheral arterial disease (PAD). This can be used to identify patients with significant impairment and to monitor effectiveness of therapeutic interventions. The questionnaire was self-administered by the patients and contains three domains measuring three important factors of walking impairment in patients with intermittent claudication: (1) difficulty walking a distance during the past month, (2) difficulty walking at a certain speed during the past month, (3) symptoms associated with walking impairment. For each separate domain, a subscore was calculated. The total WIQ score was defined as the mean of the three subscores. A WIQ score of 42.5 or less identified low performers; while a score of 75.5 or more identified high performers. The WIQ score range is 0 (minimum) - 100 (maximum).
Time Frame
12 months
Title
MAE (Major Adverse Events)
Description
Percentage of participants with a MAE (Major Adverse Events) at 1 year. Major Adverse Events, defined as Death of any Cause, Major Amputation of target limb, Minor Amputation of target limb
Time Frame
12 months
Title
Device Success
Description
Percentage of device success defined as exact deployment of the device according to the instructions for use as documented with suitable imaging modalities
Time Frame
Day 1
Title
Technical Success
Description
Percentage of technical success defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with less or equal to 50% residual diameter reduction of the treated lesion on completion angiography
Time Frame
Day 1
Title
Procedural Success
Description
Percentage of patients with a procedural success defined as combination of technical success, device success and absence of procedural complications
Time Frame
Day 1
Title
Days of Hospitalization
Description
Days of hospitalization at 1 year
Time Frame
12 months
Title
Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA)
Description
Percentage of participants with an improvement in percent diameter stenosis (%DS) of the target leasion (TL) assessed by Quantitative Vascular Angiography (QVA)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: General Inclusion Criteria Age ≥18 years and ≤85 years Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an Ethical Committee approved consent form Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 4, 5 or 6 Life expectancy >1 year in the Investigator's opinion General Angiographic Inclusion Criteria Reference vessel(s) diameter between 2 and 4 mm Single or multiple lesions with ≥70% diameter stenosis (DS) of different lengths in one or more main afferent crural vessels including the tibioperoneal trunk At least one non occluded crural vessel with angiographically documented run-off to the foot either direct or through collaterals Angiographic Inclusion Criteria for Late Lumen Loss (LLL) assessment Angio-target lesion (TL) is one identifiable single solitary or series of multiple adjacent lesions with a diameter stenosis (DS) ≥70% and a cumulative length ≤100 mm that can be covered by a single IN.PACT Amphirion™ (10 mm balloon landing zone in both edges is mandatory) Angio-target lesion (TL) is the only lesion in that vessel (only one Angio-TL per patient is allowed) Exclusion Criteria: General Exclusion Criteria Patient unwilling or unlikely to comply with Follow-Up schedule Planned major index limb amputation General Angiographic Exclusion Criteria Lesion and / or occlusions located or extending in the popliteal artery or below the ankle joint space Inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA), popliteal arteries with length ≥15 cm Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA) and popliteal arteries left untreated Previously implanted stent in the target lesions(s) Aneurysm in the target vessel Acute thrombus in the target limb General Procedural Exclusion Criteria Failure to obtain a <30% residual stenosis in pre-existing, hemodynamically significant (≥50% diameter stenosis (DS) and <15 cm length) inflow lesions in the ipsilateral iliac, SFA and popliteal artery. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions. Failure to cross the TL with a 0.014" guide wire Use of alternative therapy, e.g. atherectomy, cutting balloon, laser, radiation therapy, DES as part of the index procedure ANGIOGRAPHIC cohort General Exclusion Criteria: - Glomerular Filtration Rate (GFR) <30 ml/min except for patients with renal end stage disease on chronic haemodialysis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dierk Scheinert, MD
Organizational Affiliation
Heart Center Leipzig - University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Thomas Zeller, MD
Organizational Affiliation
University Heart Center Freiburg - Bad Krozingen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Iris Baumgartner, MD
Organizational Affiliation
Insel Gruppe AG, University Hospital Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University Graz
City
Graz
Country
Austria
Facility Name
Imelda Hospital
City
Bonheiden
Country
Belgium
Facility Name
AZ Sint-Blasius
City
Dendermonde
Country
Belgium
Facility Name
ZOL St. Jan
City
Genk
Country
Belgium
Facility Name
Ghent University Hospital
City
Gent
Country
Belgium
Facility Name
Herz-Zentrum Bad Krozingen
City
Bad Krozingen
ZIP/Postal Code
79189
Country
Germany
Facility Name
Medical Care Center
City
Hamburg
Country
Germany
Facility Name
University Hospital Heidelberg
City
Heidelberg
Country
Germany
Facility Name
Park-Krankenhaus Leipzig
City
Leipzig
ZIP/Postal Code
04289
Country
Germany
Facility Name
Villa Maria Eleonora Hospital
City
Palermo
Country
Italy
Facility Name
St. Antonius Hospital
City
Nieuwegein
Country
Netherlands
Facility Name
University of Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Luzerner Kantonsspital
City
Luzern
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
32081236
Citation
Zeller T, Micari A, Scheinert D, Baumgartner I, Bosiers M, Vermassen FEG, Banyai M, Shishehbor MH, Wang H, Brodmann M; IN.PACT DEEP Trial Investigators. The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes. JACC Cardiovasc Interv. 2020 Feb 24;13(4):431-443. doi: 10.1016/j.jcin.2019.10.059.
Results Reference
derived
PubMed Identifier
25301459
Citation
Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, Peeters P, Vermassen F, Landini M, Snead DB, Kent KC, Rocha-Singh KJ; IN.PACT DEEP Trial Investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014 Oct 14;64(15):1568-76. doi: 10.1016/j.jacc.2014.06.1198.
Results Reference
derived
PubMed Identifier
24552184
Citation
Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, Peeters P, Vermassen F, Landini M; IN.PACT DEEP Trial Investigators. IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. Trials. 2014 Feb 19;15:63. doi: 10.1186/1745-6215-15-63.
Results Reference
derived
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/24552184
Description
Zeller et al. Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapoplliteal Arterial Revascularization in CLI - 12-Month Results from the IN.PACT DEEP Randomized trial.Journal of the American College of Cardiology 2014; 64; 15

Learn more about this trial

Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia

We'll reach out to this number within 24 hrs